Condition: Cervical Cancer · Breast Cancer · Colon Cancer · Sponsor: Orano Med Theranostics, SAS
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors
This description comes directly from the study's public registry record.
Orano Med LLC · 469-638-0744 · clinicaltrials@oranomed.com
Always discuss trial participation with your own doctor first.
| Northwestern University Robert H Lurie Medical Research | Chicago, Illinois, United States | Active Not Recruiting |
| University of Iowa Health Care | Iowa City, Iowa, United States | Not Yet Recruiting |
| UK Markey Cancer Center | Lexington, Kentucky, United States | Recruiting |
| Advanced Molecular Imaging and Therapy | Glen Burnie, Maryland, United States | Recruiting |
| United Theranostics - Chesapeake | Glen Burnie, Maryland, United States | Not Yet Recruiting |
| Nebraska Cancer Specialists (Midwest Cancer Center - Legacy) | Omaha, Nebraska, United States | Recruiting |
| XCancer Omaha / Urology Cancer Center | Omaha, Nebraska, United States | Recruiting |
| University of Pittsburg Medical Center (UPCM) | Pittsburgh, Pennsylvania, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05283330